561-845-0500 | Palm Beach ashpriresearch@aol.com

Alzheimer’s Disease

Participate in an Alzheimer’s Research Study

If you or someone you love is experiencing memory loss, or has been diagnosed with Alzheimer’s disease, perhaps you should consider participating in a clinical research study. Participants receive a high standard of care, and research shows that people involved in clinical trials tend to do somewhat better than people in a similar stage of their disease who are not enrolled in clinical trials.*

Health insurance is not necessary to participate. Patients who qualify for our clinical trials will receive all study related care and treatment at no cost. In some cases you may be compensated for your time and travel. You may even gain access to research treatments before they are widely available.

Interested in learning about our Alzheimer’s research studies? Contact the Premiere Research Institute of Palm Beach by calling (561) 296-3824 or fill out the form below.


Your Name:*

Your Email:*

Your Phone Number:*


Perhaps the best reason to participate in an Alzheimer’s clinical trial is so that you can take an active role in your health care, by educating yourself regarding your condition. You will obtain access to top quality medical care from our Board Certified physicians at a medical research healthcare facility specializing in Alzheimer’s care.

Without volunteers for clinical trials, improved treatments, including a cure for Alzheimer’s disease can never become a reality.

Premiere Research Institute is currently seeking volunteers for the A4 Study.

If you are a healthy older adult with normal memory, this could be the right time for you to join the fight to prevent the memory loss associated with Alzheimer’s disease.

What is the A4 study?

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study “for short) is a clinical study for older individuals (65 to 85 years of age) who may be at risk for the memory loss associated with Alzheimer’s disease (AD).

The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss. The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.

Am I eligible?

The A4 study will enroll 1,000 people between the ages of 65 through 85 with normal thinking and memory function but with evidence of amyloid plaque buildup in the brain. Physicians and researchers will use PET amyloid imaging scans to determine whether a potential participant has evidence of elevated amyloid buildup. Individuals with elevated amyloid on the PET scan will be eligible to become participants in the A4 clinical study. People who do not show evidence of elevated brain amyloid may be asked to participate in a separate study. This group will not receive the study drug but will complete the same memory tests every six months to compare changes in cognition over time.

* Source: alz.org (official website for the Alzheimer’s Association)

Articles about Alzheimer’s Disease

To read one of our most recent articles about Alzheimer’s Disease just click the title of the article.

Our Doctors

To view a brief description of the specialties and background of each of our physicians click on their name.

Our Newsletter was created to educate and inform our readers regarding the newest treatments, articles, and research that are being conducted in the field of Neurology.